MARKET

XNCR

XNCR

Xencor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.26
-2.42
-5.42%
After Hours: 42.26 0 0.00% 16:19 04/16 EDT
OPEN
45.20
PREV CLOSE
44.68
HIGH
45.20
LOW
41.53
VOLUME
212.18K
TURNOVER
--
52 WEEK HIGH
58.35
52 WEEK LOW
26.80
MARKET CAP
2.45B
P/E (TTM)
-34.8565
1D
5D
1M
3M
1Y
5Y
Global Allergic Conjunctivitis Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Allergic Conjunctivitis Drug market report provides a detailed analysis of global market size, regional and country-level...
Heraldkeepers · 2d ago
Global Lymphocyte Activation Gene 3 Protein Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Lymphocyte Activation Gene 3 Protein market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 2d ago
The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14)
Benzinga · 2d ago
Xencor Inc Shares Down 19.4% Since SmarTrend's Sell Call (XNCR)
Apr 13, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Xencor Inc (NASDAQ:XNCR) on February 23rd, 2021 at $49.17. In...
marketwatch.com · 4d ago
Xencor Presents Positive Data For XmAb Antibodies Program Against Cancer
Xencor presented new data from multiple preclinical studies for XmAb bispecific antibody and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting. Xencor’s (XNCR) IL-12-Fc cytokine program is based...
SmarterAnalyst · 5d ago
Xencor Saturday Morning Announced New Data From Multiple XmAb® Bispecific Antibody and Cytokine Programs At American Association For Cancer Research Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of
Benzinga · 5d ago
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmA...
Business Wire · 04/10 13:30
Inmune Bio files to sell 1.7M shares from shareholder Xencor
Inmune Bio (INMB) has filed for an offering to sell ~1.7M shares from shareholder Xencor (XNCR).The maximum aggregate offering price is ~$20.35M.After the offering, Xencor will own ~14% of outstanding
Seekingalpha · 04/09 21:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XNCR. Analyze the recent business situations of Xencor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XNCR stock price target is 54.75 with a high estimate of 63.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 239
Institutional Holdings: 63.58M
% Owned: 109.72%
Shares Outstanding: 57.95M
TypeInstitutionsShares
Increased
55
1.88M
New
26
272.89K
Decreased
70
2.23M
Sold Out
9
93.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
President/Chief Executive Officer/Founder/Director
Bassil Dahiyat
Chief Financial Officer/Vice President
John Kuch
Senior Vice President/Chief Scientific Officer
John Desjarlais
Senior Vice President
Allen Yang
Vice President/General Counsel/Secretary
Celia Eckert
Lead Director/Independent Director
A. Montgomery
Vice President
Jeremy Grunstein
Vice President
Eric Kowack
Vice President
Kirk Rosemark
Other
Julie Casciani
Lead Director/Independent Director
A. Bruce Montgomery
Independent Director
Ellen Feigal
Independent Director
Kevin Gorman
Independent Director
Kurt Gustafson
Independent Director
Yujiro Hata
Independent Director
Richard Ranieri
Independent Director
Dagmar Rosa-Bjorkeson
No Data
  • All
  • Financials
  • Insiders
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Webull offers kinds of Xencor Inc stock information, including NASDAQ:XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.